Until now, the vast majority of the studies on cardioprotection have been performed mostly on anthracyclines and, in the case of breast cancer, on anthracyclines + trastuzumab [30, 146] and have been proposing dexrazoxane [147], ACE inhibitors [148], and statins [149, 150] (Table 1). Here, ACE is linked to breast cancer.